MLND - Millendo Therapeutics: A Forgotten Biotech With Strong Potential

Millendo Therapeutics (MLND) is a solid biotech, which has already received positive results from a proof of concept study using livoletide to treat patients with Prader-Willi Syndrome ((PWS)). Based on positive preliminary data, it was able to initiate a phase 2b/3 study. There is a big catalyst coming up in the early part of 2020. Specifically, Millendo will report results from the phase 2b/3 study in the first half of 2020. These results will be a major catalyst for the biotech. Assuming the phase 2b portion turns out to meet the primary endpoints,

Read more ...